PTC Therapeutics, Inc.
NASDAQ:PTCTBiotechnology
+$0.60 today
- Market cap
- $5.03B
- Beta
- 0.55
- P/E (TTM)
- -35.0
- EPS (TTM)
- -$2.26
Volume 0.64M
Average 1.27M
PTCT Total Liabilities
Everything the company owes to creditors and other parties.
PTC Therapeutics, Inc.NASDAQ: PTCT
Total Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total liabilities rises 20.2% from a year ago
Total liabilities stood at $3.42B at the end of Q2 FY2026, up 20.2% from a year earlier and up 12.0% from the prior quarter. Over 3 fiscal years it compounded at +14.8% a year.
Context
- Total liabilities amounted to 105.1% of total assets at the end of Q2 FY2026, down 2.8 pp from a year earlier.
- Total liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +20.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 3.1B USD
- Year-over-year change
- +10.7%
- 4-year CAGR
- +12.5%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.1B | +10.7% |
| FY2024 | 2024-12-31 | 2.8B | +3.3% |
| FY2023 | 2023-12-31 | 2.71B | +32.2% |
| FY2022 | 2022-12-31 | 2.05B | +6.0% |
| FY2021 | 2021-12-31 | 1.94B | — |
Total Liabilities vs competitors
How PTCT compares with its peers on the latest reported figures
- PTCT's Jun 2026 total liabilities of $3.42B is the 3rd highest of the 11 companies compared; the peer median is $908.43M.
- Its year-over-year change of +20.2% is the 7th highest of 11, against a peer median of +30.8%.
- Total liabilities amounts to 105.1% of total assets for PTCT, versus a peer median of 37.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $5.31T | +340892.5% | -5.3% | 45.9% | |
| Jun 2026 | $3.72B | +30.2% | +17.3% | 305.9% | |
| Jun 2026 | $3.42B | +20.2% | +14.8% | 105.1% | |
| Sep 2026 | $2.52B | +4.3% | +15.7% | 86.5% | |
| Mar 2026 | $1.67B | -27.9% | -7.0% | 52.7% | |
| Mar 2026 | $1.53B | +31.4% | +10.4% | 117.7% | |
| Jun 2026 | $291.86M | +85.3% | +58.5% | 29.4% | |
| Jun 2026 | $141.52M | +44.8% | +46.7% | 9.4% | |
| Mar 2026 | $71.81M | -38.4% | -16.3% | 12.3% | |
| Mar 2026 | $48.76M | -1.4% | +2.6% | 11.5% | |
| Mar 2026 | $47.58M | +82.2% | +9.4% | 14.6% | |
| Peer median (excluding PTCT) | $908.43M | +30.8% | +9.9% | 37.6% | |
Competitors are the stored peer set for PTCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 189.72M | 279.83M | 594M | 779.71M | 984.65M |
| Short-term Investments | 583.66M | 130.87M | 282.74M | 359.99M | 960.72M |
| Net Receivables | 110.46M | 155.61M | 160.82M | 158.55M | 181.62M |
| Inventory | 15.86M | 21.81M | 30.58M | 23.19M | 79.65M |
| Other Current Assets | 0 | 105.66M | 150.49M | 44.09M | 67.31M |
| Total Current Assets | 954.37M | 693.79M | 1.22B | 1.37B | 2.27B |
| Property, Plant & Equipment (Net) | 130.01M | 175.02M | 178.99M | 117.66M | 135.42M |
| Goodwill | 82.34M | 82.34M | 82.34M | 82.34M | 82.34M |
| Intangible Assets | 724.84M | 705.89M | 379.5M | 118.79M | 388.75M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 46.5M | 48.58M | 36.25M | 20.7M | 18.3M |
| Total Non-current Assets | 983.69M | 1.01B | 677.07M | 339.49M | 624.82M |
| Total Assets | 1.94B | 1.71B | 1.9B | 1.71B | 2.9B |
| Account Payables | 23.03M | 27.27M | 6.05M | 17.27M | 45.49M |
| Short-term Debt | 208.83M | 72.15M | 194.31M | 257.82M | 569.63M |
| Tax Payables | 1.29M | 4.71M | 0 | 4.7M | 0 |
| Deferred Revenue | 0 | 1.35M | 801K | 5.51M | 2.04M |
| Other Current Liabilities | 118.86M | 126.46M | 139.82M | 120.22M | 202.93M |
| Total Current Liabilities | 509.35M | 406.24M | 603.1M | 580.98M | 968.43M |
| Long-term Debt | 956.59M | 1.26B | 1.9B | 2.11B | 2.03B |
| Deferred Tax Liabilities | 137.11M | 102.83M | 55.91M | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 239.9M | 166.64M | 36.44M | 22.23M | 13.7M |
| Total Non-current Liabilities | 1.43B | 1.65B | 2.11B | 2.22B | 2.14B |
| Total Liabilities | 1.94B | 2.05B | 2.71B | 2.8B | 3.1B |
| Common Stock | 71K | 72K | 75K | 77K | 80K |
| Retained Earnings | (2.1B) | (2.66B) | (3.28B) | (3.65B) | (2.96B) |
| Accumulated OCI | (24.28M) | 4.8M | (1.29M) | (25.89M) | 10.5M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 1.44M | (347.09M) | (818.56M) | (1.1B) | (205.31M) |
| Total Debt | 1.27B | 1.46B | 2.23B | 2.47B | 2.71B |
| Net Debt | 1.08B | 1.18B | 1.64B | 1.69B | 1.72B |
PTC Therapeutics, Inc.
NASDAQ:PTCT
Intrinsic Alpha fair value
Locked
Current Price
$60.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.